The Baron Health Care Fund has recently highlighted Roivant Sciences (NasdaqGS:ROIV) due to positive Phase 2 results for brepocitinib in cutaneous sar...
Bearish
An officer of Roivant Sciences (ROIV.US), Venker Eric, sold 200,000 shares of common stock on April 20, 2026. The transaction was valued at approximat...
Roivant Sciences Ltd. director Melissa B. Epperly was granted 670 fully vested common shares as equity compensation under the company's Non-Employee D...
Roivant Sciences Ltd. director James C. Momtazee received a grant of 469 common shares under the company's Non-Employee Director Compensation Plan. To...
Bearish
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share, totaling app...